Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria

  18 June 2022

Ceftriaxone resistance combined with high-level azithromycin resistance in  is a concern for future treatment of gonorrhoea and poses a major global public health threat. Improved prevention (including condom use), early and accurate diagnosis and effective, affordable and accessible treatment (ideally including test of cure and contact notification and treatment) of gonorrhoea are imperative. Furthermore, increased awareness of the spread of ceftriaxone-resistant strains and rapid identification and eradication of the sporadic XDR gonococcal strains are essential to avoid any clonal expansion and sustained transmission of these strains. Enhanced antimicrobial resistance surveillance, ideally including test of cure and whole-genome sequencing, nationally and internationally, particularly in Asia where many ceftriaxone-resistant strains appear to have emerged, is of highest importance. Ultimately, novel antimicrobials for effective treatment of gonorrhoea and/or a sufficiently effective gonococcal vaccine will be crucial.

Further reading: Eurosurveillance
Author(s): Sonja Pleininger et al
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed